-
ABOUT USHebei Guangxiang Pharmaceutical Co., Ltd. is specializing in the production of bulk pharmaceuticals, fine pharmaceuticals, intermediate compounds and biopharmaceutical preparations.
-
News CenterAt the forefront of corporate development, we champion the positive energy of the Four Pharmaceutical Companies: fulfilling our duties conscientiously, stepping up to the plate and taking proactive action, embracing new missions, and conducting effective new publicity. In doing so, we aim to enhance the overall competence of our employees, stimulate their enthusiasm, initiative, and creativity, and provide robust ideological guidance and powerful spiritual strength to drive the enterprise forward.
-
INNOVATIONDevelops fine, series, high-end bulk pharmaceutical intermediates and innovative bulk pharmaceutical intermediates with high added value to build variety competition advantages.
-
-
RECRUITGuangxiang has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities.
-
CONTACTWith stable production, high-quality and reliable service, the company's products have been sold to more than 80 countries such as the United States, the United Kingdom, Germany and the Netherlands
Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Approval for Lacosamide API
Category:
TIME：2022-05-17
【SUMMARY】
Another piece of good news has emerged from the research efforts of Shijiazhuang Sihua Pharmaceutical Group. Recently, the active pharmaceutical ingredient lacosamide, developed and submitted for approval by the Group’s Hebei Guangxiang Pharmaceutical Co., Ltd., was approved by the National Medical Products Administration and may now be officially used in marketed dosage forms.
Another piece of good news has emerged from the research efforts at Shijiazhuang No. 4 Pharmaceutical Group. Recently, the active pharmaceutical ingredient lacosamide, developed and submitted for approval by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang No. 4 Pharmaceutical Group, has been approved by the National Medical Products Administration, paving the way for its official use in marketed dosage forms.
According to reports, lacosamide formulations are primarily used in clinical practice for monotherapy and combination therapy of partial-onset seizures in patients aged 4 years and older with epilepsy.
Previously, Shijiazhuang Sihua Pharmaceutical’s lacosamide tablets in 50 mg and 100 mg strengths received drug registration certificates from the National Medical Products Administration and were deemed to have passed the evaluation of quality and therapeutic equivalence for generic drugs. The recent approval of the lacosamide API will further enhance the product’s market competitiveness.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
E-mail: hbgxzy@hebgxzy.com
Address: The west of Jingliu Road, lingang economic nad technological development zone, cangzhou city, Hebei province
Website
Official WeChat
e-Home
Business License
